A reevaluation of CD22 expression in human lung cancer

Laurentiu M. Pop, Stephen Barman, Chunli Shao, Jonathan C. Poe, Guglielmo M. Venturi, John M. Shelton, Iliodora V. Pop, David E. Gerber, Luc Girard, Xiao Yun Liu, Carmen Behrens, Jaime Rodriguez-Canales, Hui Liu, Ignacio I. Wistuba, James A. Richardson, John D. Minna, Thomas F. Tedder, Ellen S. Vitetta

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

CD22 is a transmembrane glycoprotein expressed by mature B cells. It inhibits signal transduction by the B-cell receptor and its coreceptor CD19. Recent reports indicate that most human lung cancer cells and cell lines express CD22, making it an important new therapeutic target for lung cancer. The objective of our studies was to independently validate these results with the goal of testing the efficacy of our CD22 immunotoxins on lung cancer cell lines. As determined by quantitative real-time PCR analysis, we found that levels of CD22 mRNA in a panel of human lung cancer cell lines were 200 to 60,000-fold lower than those observed in the human CD22+ Burkitt lymphoma cells, Daudi. Using flow cytometry with a panel of CD22 monoclonal antibodies and Western blot analyses, we could not detect surface or intracellular expression of CD22 protein in a panel of lung cancer cell lines. In addition, the in vitro proliferation of the lung tumor cell lines was not affected by either CD22 antibodies or our highly potent anti-CD22 immunotoxin. In contrast, CD22 + Daudi cells expressed high levels of CD22mRNA and protein, and were sensitive to our CD22 immunotoxin. Importantly, primary non-small cell lung cancers from more than 250 patient specimens did not express detectable levels of CD22 protein as assessed by immunohistochemistry. We conclude that CD22 is not expressed at measurable levels on the surface of lung cancer cells, and that these cells cannot be killed by anti-CD22 immunotoxins.

Original languageEnglish (US)
Pages (from-to)263-271
Number of pages9
JournalCancer Research
Volume74
Issue number1
DOIs
StatePublished - Jan 1 2014

Fingerprint

Immunotoxins
Lung Neoplasms
Cell Line
B-Lymphocytes
Proteins
Burkitt Lymphoma
Tumor Cell Line
Non-Small Cell Lung Carcinoma
Real-Time Polymerase Chain Reaction
Signal Transduction
Glycoproteins
Flow Cytometry
Western Blotting
Immunohistochemistry
Monoclonal Antibodies
Lung
Messenger RNA
Antibodies
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A reevaluation of CD22 expression in human lung cancer. / Pop, Laurentiu M.; Barman, Stephen; Shao, Chunli; Poe, Jonathan C.; Venturi, Guglielmo M.; Shelton, John M.; Pop, Iliodora V.; Gerber, David E.; Girard, Luc; Liu, Xiao Yun; Behrens, Carmen; Rodriguez-Canales, Jaime; Liu, Hui; Wistuba, Ignacio I.; Richardson, James A.; Minna, John D.; Tedder, Thomas F.; Vitetta, Ellen S.

In: Cancer Research, Vol. 74, No. 1, 01.01.2014, p. 263-271.

Research output: Contribution to journalArticle

Pop, LM, Barman, S, Shao, C, Poe, JC, Venturi, GM, Shelton, JM, Pop, IV, Gerber, DE, Girard, L, Liu, XY, Behrens, C, Rodriguez-Canales, J, Liu, H, Wistuba, II, Richardson, JA, Minna, JD, Tedder, TF & Vitetta, ES 2014, 'A reevaluation of CD22 expression in human lung cancer', Cancer Research, vol. 74, no. 1, pp. 263-271. https://doi.org/10.1158/0008-5472.CAN-13-1436
Pop LM, Barman S, Shao C, Poe JC, Venturi GM, Shelton JM et al. A reevaluation of CD22 expression in human lung cancer. Cancer Research. 2014 Jan 1;74(1):263-271. https://doi.org/10.1158/0008-5472.CAN-13-1436
Pop, Laurentiu M. ; Barman, Stephen ; Shao, Chunli ; Poe, Jonathan C. ; Venturi, Guglielmo M. ; Shelton, John M. ; Pop, Iliodora V. ; Gerber, David E. ; Girard, Luc ; Liu, Xiao Yun ; Behrens, Carmen ; Rodriguez-Canales, Jaime ; Liu, Hui ; Wistuba, Ignacio I. ; Richardson, James A. ; Minna, John D. ; Tedder, Thomas F. ; Vitetta, Ellen S. / A reevaluation of CD22 expression in human lung cancer. In: Cancer Research. 2014 ; Vol. 74, No. 1. pp. 263-271.
@article{cb649c5d637d4ec5b31fee833b2a9188,
title = "A reevaluation of CD22 expression in human lung cancer",
abstract = "CD22 is a transmembrane glycoprotein expressed by mature B cells. It inhibits signal transduction by the B-cell receptor and its coreceptor CD19. Recent reports indicate that most human lung cancer cells and cell lines express CD22, making it an important new therapeutic target for lung cancer. The objective of our studies was to independently validate these results with the goal of testing the efficacy of our CD22 immunotoxins on lung cancer cell lines. As determined by quantitative real-time PCR analysis, we found that levels of CD22 mRNA in a panel of human lung cancer cell lines were 200 to 60,000-fold lower than those observed in the human CD22+ Burkitt lymphoma cells, Daudi. Using flow cytometry with a panel of CD22 monoclonal antibodies and Western blot analyses, we could not detect surface or intracellular expression of CD22 protein in a panel of lung cancer cell lines. In addition, the in vitro proliferation of the lung tumor cell lines was not affected by either CD22 antibodies or our highly potent anti-CD22 immunotoxin. In contrast, CD22 + Daudi cells expressed high levels of CD22mRNA and protein, and were sensitive to our CD22 immunotoxin. Importantly, primary non-small cell lung cancers from more than 250 patient specimens did not express detectable levels of CD22 protein as assessed by immunohistochemistry. We conclude that CD22 is not expressed at measurable levels on the surface of lung cancer cells, and that these cells cannot be killed by anti-CD22 immunotoxins.",
author = "Pop, {Laurentiu M.} and Stephen Barman and Chunli Shao and Poe, {Jonathan C.} and Venturi, {Guglielmo M.} and Shelton, {John M.} and Pop, {Iliodora V.} and Gerber, {David E.} and Luc Girard and Liu, {Xiao Yun} and Carmen Behrens and Jaime Rodriguez-Canales and Hui Liu and Wistuba, {Ignacio I.} and Richardson, {James A.} and Minna, {John D.} and Tedder, {Thomas F.} and Vitetta, {Ellen S.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1158/0008-5472.CAN-13-1436",
language = "English (US)",
volume = "74",
pages = "263--271",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - A reevaluation of CD22 expression in human lung cancer

AU - Pop, Laurentiu M.

AU - Barman, Stephen

AU - Shao, Chunli

AU - Poe, Jonathan C.

AU - Venturi, Guglielmo M.

AU - Shelton, John M.

AU - Pop, Iliodora V.

AU - Gerber, David E.

AU - Girard, Luc

AU - Liu, Xiao Yun

AU - Behrens, Carmen

AU - Rodriguez-Canales, Jaime

AU - Liu, Hui

AU - Wistuba, Ignacio I.

AU - Richardson, James A.

AU - Minna, John D.

AU - Tedder, Thomas F.

AU - Vitetta, Ellen S.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - CD22 is a transmembrane glycoprotein expressed by mature B cells. It inhibits signal transduction by the B-cell receptor and its coreceptor CD19. Recent reports indicate that most human lung cancer cells and cell lines express CD22, making it an important new therapeutic target for lung cancer. The objective of our studies was to independently validate these results with the goal of testing the efficacy of our CD22 immunotoxins on lung cancer cell lines. As determined by quantitative real-time PCR analysis, we found that levels of CD22 mRNA in a panel of human lung cancer cell lines were 200 to 60,000-fold lower than those observed in the human CD22+ Burkitt lymphoma cells, Daudi. Using flow cytometry with a panel of CD22 monoclonal antibodies and Western blot analyses, we could not detect surface or intracellular expression of CD22 protein in a panel of lung cancer cell lines. In addition, the in vitro proliferation of the lung tumor cell lines was not affected by either CD22 antibodies or our highly potent anti-CD22 immunotoxin. In contrast, CD22 + Daudi cells expressed high levels of CD22mRNA and protein, and were sensitive to our CD22 immunotoxin. Importantly, primary non-small cell lung cancers from more than 250 patient specimens did not express detectable levels of CD22 protein as assessed by immunohistochemistry. We conclude that CD22 is not expressed at measurable levels on the surface of lung cancer cells, and that these cells cannot be killed by anti-CD22 immunotoxins.

AB - CD22 is a transmembrane glycoprotein expressed by mature B cells. It inhibits signal transduction by the B-cell receptor and its coreceptor CD19. Recent reports indicate that most human lung cancer cells and cell lines express CD22, making it an important new therapeutic target for lung cancer. The objective of our studies was to independently validate these results with the goal of testing the efficacy of our CD22 immunotoxins on lung cancer cell lines. As determined by quantitative real-time PCR analysis, we found that levels of CD22 mRNA in a panel of human lung cancer cell lines were 200 to 60,000-fold lower than those observed in the human CD22+ Burkitt lymphoma cells, Daudi. Using flow cytometry with a panel of CD22 monoclonal antibodies and Western blot analyses, we could not detect surface or intracellular expression of CD22 protein in a panel of lung cancer cell lines. In addition, the in vitro proliferation of the lung tumor cell lines was not affected by either CD22 antibodies or our highly potent anti-CD22 immunotoxin. In contrast, CD22 + Daudi cells expressed high levels of CD22mRNA and protein, and were sensitive to our CD22 immunotoxin. Importantly, primary non-small cell lung cancers from more than 250 patient specimens did not express detectable levels of CD22 protein as assessed by immunohistochemistry. We conclude that CD22 is not expressed at measurable levels on the surface of lung cancer cells, and that these cells cannot be killed by anti-CD22 immunotoxins.

UR - http://www.scopus.com/inward/record.url?scp=84892755101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892755101&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-13-1436

DO - 10.1158/0008-5472.CAN-13-1436

M3 - Article

C2 - 24395821

AN - SCOPUS:84892755101

VL - 74

SP - 263

EP - 271

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 1

ER -